Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva

Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP due to blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikishina, Irina P., Arsenyeva, Svetlana V., Matkava, Valeria G., Arefieva, Alia N., Kaleda, Mariya I., Smirnov, Alexandr V., Blank, Leonid M., Kostik, Mikhail M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464034/
https://www.ncbi.nlm.nih.gov/pubmed/37644581
http://dx.doi.org/10.1186/s12969-023-00856-1
_version_ 1785098373415567360
author Nikishina, Irina P.
Arsenyeva, Svetlana V.
Matkava, Valeria G.
Arefieva, Alia N.
Kaleda, Mariya I.
Smirnov, Alexandr V.
Blank, Leonid M.
Kostik, Mikhail M.
author_facet Nikishina, Irina P.
Arsenyeva, Svetlana V.
Matkava, Valeria G.
Arefieva, Alia N.
Kaleda, Mariya I.
Smirnov, Alexandr V.
Blank, Leonid M.
Kostik, Mikhail M.
author_sort Nikishina, Irina P.
collection PubMed
description Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP due to blocking multiple signaling pathways.
format Online
Article
Text
id pubmed-10464034
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104640342023-08-30 Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva Nikishina, Irina P. Arsenyeva, Svetlana V. Matkava, Valeria G. Arefieva, Alia N. Kaleda, Mariya I. Smirnov, Alexandr V. Blank, Leonid M. Kostik, Mikhail M. Pediatr Rheumatol Online J Research Article Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP due to blocking multiple signaling pathways. BioMed Central 2023-08-29 /pmc/articles/PMC10464034/ /pubmed/37644581 http://dx.doi.org/10.1186/s12969-023-00856-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Nikishina, Irina P.
Arsenyeva, Svetlana V.
Matkava, Valeria G.
Arefieva, Alia N.
Kaleda, Mariya I.
Smirnov, Alexandr V.
Blank, Leonid M.
Kostik, Mikhail M.
Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva
title Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva
title_full Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva
title_fullStr Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva
title_full_unstemmed Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva
title_short Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva
title_sort successful experience of tofacitinib treatment in patients with fibrodysplasia ossificans progressiva
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464034/
https://www.ncbi.nlm.nih.gov/pubmed/37644581
http://dx.doi.org/10.1186/s12969-023-00856-1
work_keys_str_mv AT nikishinairinap successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva
AT arsenyevasvetlanav successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva
AT matkavavaleriag successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva
AT arefievaalian successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva
AT kaledamariyai successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva
AT smirnovalexandrv successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva
AT blankleonidm successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva
AT kostikmikhailm successfulexperienceoftofacitinibtreatmentinpatientswithfibrodysplasiaossificansprogressiva

Ejemplares similares